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Background: Wnt proteins are important for developmental processes and certain diseases. WNT5A is a non-canonical
Wnt protein that previously has been shown to play a role in the progression of malignant melanoma. High expression
of WNT5A in melanoma tumors correlates to formation of distant metastasis and poor prognosis. This has partly been
described by the findings that WNT5A expression in melanoma cell lines increases migration and invasion.
Methods: Malignant melanoma cell lines were treated with rWNT5A or WNT5A siRNA, and mRNA versus protein levels
of soluble mediators were measured using RT-PCR, cytokine bead array and ELISA. The induced signaling pathways
were analyzed using inhibitors, Rho-GTPase pull down assays and western blot. Ultracentrifugation and electron
microscopy was used to analyze microvesicles. Gene expression microarray data obtained from primary malignant
melanomas was used to verify our data.
Results: We show that WNT5A signaling induces a Ca2+-dependent release of exosomes containing the
immunomodulatory and pro-angiogenic proteins IL-6, VEGF and MMP2 in melanoma cells. The process was
independent of the transcriptional machinery and depletion of WNT5A reduced the levels of the exosome-derived
proteins. The WNT5A induced exosomal secretion was neither affected by Tetanus toxin nor Brefeldin A, but was
blocked by the calcium chelator Bapta, inhibited by a dominant negative version of the small Rho-GTPase Cdc42 and
was accompanied by cytoskeletal reorganization. Co-cultures of melanoma/endothelial cells showed that depletion of
WNT5A in melanoma cells decreased endothelial cell branching, while stimulation of endothelial cells with isolated
rWNT5A-induced melanoma exosomes increased endothelial cell branching in vitro. Finally, gene expression data
analysis of primary malignant melanomas revealed a correlation between WNT5A expression and the angiogenesis
marker ESAM.
Conclusions: These data indicate that WNT5A has a broader function on tumor progression and metastatic spread
than previously known; by inducing exosome-release of immunomodulatory and pro-angiogenic factors that enhance
the immunosuppressive and angiogenic capacity of the tumors thus rendering them more aggressive and more prone
to metastasize.
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Wnt signaling proteins are a family of highly conserved
proteins that are important during developmental pro-
cesses. They have also been implicated in several diseases,
such as cancer and diseases with an inflammatory com-
ponent [1,2]. Canonical Wnt signaling, exemplified by
WNT3A, is the most well characterized Wnt signaling
pathway, leading to activation of β-catenin [1,3]. Non-
canonical signaling via WNT5A can inhibit β-catenin
signaling but also activate distinct signaling pathways, in-
dependent of β-catenin. Activation of non-canonical
WNT5A signaling can lead to several different outcomes,
such as activation of Ca2+ signaling, activation of small
Rho-GTPases (Cdc42, Rac1 and RhoA), Calmodulin-
Kinase II, PKC, PKA, and JNK [3-5].
Malignant melanoma is a highly aggressive cancer
form which once spread, has a 5-year survival rate of 5%
[6]. For the tumor to spread to distant sites, the for-
mation of new vessels is required, a process known as
angiogenesis. In malignant melanoma, angiogenesis is
correlated to the transition of the tumor from the radial
growth phase to the more invasive vertical growth phase
[7]. Several secreted factors regulate angiogenesis such
as VEGF, IL-6, Matrix metalloproteinase 2 (MMP2), IL-8
and FGF [8,9]. Some of these factors are also important
in immunomodulation and the over-expression of these,
by either the malignant melanoma cells or by infiltrating
immune cells, can lead to enhanced metastasis due to
induction of a local or systemic immunosuppression that
is beneficial for the tumor cells escape from immune
recognition and eradication [10]. The later stages of mel-
anoma including the spread to distant sites and the for-
mation of metastasis have been shown to be promoted
by an increased non-canonical WNT5A signaling. In line
with this, a high WNT5A expression was also correlated
to a poor prognosis in melanoma patients [11]. This
could partly be explained by the observations that;
in vitro, WNT5A increases migration and invasion of
malignant melanoma cells [12] and in vivo, WNT5A sig-
naling increases the spread and tumor formation of lung
metastasis [13].
Exocytosis, or cytokine secretion, is a process with im-
portant implications in most tissues and cellular systems.
Despite being widely studied, there are still questions to
be answered regarding the molecular mechanisms behind
this process [14]. Briefly, activation of specific receptors
causes an immediate release of preformed mediators from
secretory granules. Regulated exocytosis pathways that
are not constitutive in mode of action, are generally in-
duced by an increased intracellular Ca2+-signal. This sig-
nal causes a complex reorganization of the filamentous
actin (F-actin) that is facilitated by cellular mediators
such as the small Rho GTPases Cdc42 and Rac1 and
the Synaptic soluble NSF attachment protein receptors(SNAREs). Among these are the proteins syntaxins,
Soluble NSF Attachment Proteins (SNAPs) and vesicle-
associated membrane proteins (VAMPs). The VAMPs can
be divided into tetanus neurotoxin (TeNT)-sensitive
and -insensitive VAMPs [15]. Questions regarding the spe-
cific function and regulation of the actin cytoskeleton in
secretory processes have been raised. However, an in-
crease in intracellular calcium is necessary for cortical
F-actin disassembly and its subsequent reorganization.
Cdc42 and Rac1 have previously been shown to regulate
the basolateral exocytosis and secretion of cytokines in po-
larized epithelial cells [16]. It was also shown that the
polarization of cytolytic effectors in immune cells was re-
gulated by Cdc42 [17].
Exosomes are 30–90 nm non-plasma membrane-
derived vesicles that are formed in endosomal compart-
ments called multivesicular endosomes and are released
by a wide range of mammalian cells [18,19]. They contain
various molecules ranging from endosomal markers (e.g.
hsp70 and CD63) to signaling proteins (IL-6, IL-8, VEGF,
Tissue inhibitor of metalloproteinases (TIMP-1/2) and
FGFα) and mRNAs. The released exosomes merge with
and empty their content into other cells, thus contributing
to an intercellular communication. Tumor cells are known
to have an exacerbated exosome secretion that has been
linked to angiogenesis, metastatic spread and immunosup-
pression [18]. Exosome secretion can be constitutive or
regulated by for instance growth factors. The molecular
mechanism involves tetraspanins (e.g. CD63), activation of
the Rab family of proteins and probably also certain
SNAREs (e.g. Rab5b) [18-20]. Regulated exosome secre-
tion can be Ca2+-induced and dependent on cytoskeletal
reorganization [18,19]. It has previously been shown that
the exosome dependent protein Rab35, can mediate the
transport of Cdc42 and Rac1 to the plasma membrane to
remodel the actin-structures [21]. We have previously
shown that WNT5A induces an intracellular Ca2+-in-
crease in human malignant melanoma and breast cancer
cells [5,22]. We have also shown that WNT5A induced a
specific activation of Cdc42 and to some extent Rac1 in
human breast cells [5]. WNT5A has previously been
shown to activate Cdc42 and induce cytoskeletal changes
in fibroblasts [23].
Here we show, that malignant melanoma cell lines
treated with recombinant (r)WNT5A induces a pro-
minent, immediate release of immunomodulatory and
pro-angiogenic factors IL-6, IL-8, VEGF and MMP2,
while transcriptional activation of these genes remained
unaffected. The release was inhibited by calcium che-
lation and expression of a dominant negative Cdc42.
Neither Brefeldin A nor TeNT inhibited the WNT5A-
induced release of the soluble mediators. Instead we
show that WNT5A induces release of exosomes con-
taining IL-6, IL-8, VEGF and MMP2. Using gene
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from the study by Harbst et al. [24], we further revealed
a correlation between WNT5A expression and the
angiogenesis marker ESAM. We also show that knock-
down of WNT5A in malignant melanoma cells induced
a decrease in endothelial cell branching in co-culture
experiments with melanoma cells in vitro, suggesting
that WNT5A might have an effect on tumor progression
in malignant melanoma, through induction of a broad
release of soluble mediators.
Results
WNT5A increases secretion of IL-6, IL-8 and VEGF in cell
culture supernatants
It had previously been reported that WNT5A expression
was connected to the presence of the immunomodulatory
and pro-angiogenic factor IL-6 in supernatants from
malignant melanoma cells [13]. However, little evidence
exists when it comes to WNT5A induced gene expression
of IL-6. We therefore decided to analyze this in more
detail. We first determined the basal expression levels of
WNT5A protein in 5 malignant melanoma cell lines,
Mewo, SKmel28, A2058, A375 and HTB63 (also known
as HT-144). Based on the low expression of WNT5A in
Mewo and A375 cells and the high expression of WNT5A
in HTB63 cells we decided to use these three cells lines in
our further studies (Figure 1A). The Mewo cells are wild
type for the V600E BRAF mutation and the A375 and
HTB63 cell lines both carry this mutation [25,26]. We
next treated Mewo cells with recombinant WNT5A
(rWNT5A) for 3 h and measured a set of inflammatory
cytokines. As shown in Figure 1B, this short incubation
with rWNT5A induced a prominent secretion of both IL-
6 and IL-8. We subsequently confirmed the WNT5A in-
duced secretion of IL-6 using Elisa (Figure 1C). rWNT5A
also induced IL-6 secretion over a longer time period as
measured by Elisa at 3 h, 6 h, 12 h, 24 h and 48 h
(Figure 1C). We have previously shown that WNT5A in-
duces IL-10 [27] and IL-6 [28] in human monocytes. In
Mewo cells however, IL-10 was not even expressed at the
mRNA level (data not shown). The effect of IL-6 upon
rWNT5A stimulation in Mewo cells was also investigated
by RT-QPCR but there was no significant increase in IL-6
mRNA levels in Mewo cells (Figure 1D). This was also
confirmed in A375 cells (Additional file 1: Figure S1
A-B) and A2058 cells (Additional file 1: Figure S1 C-D).
PMA/ionomycin stimulation for 12 h did induce
a prominent increase in IL-6 mRNA expression in
Mewo cells showing that the Q-PCR was optimized
(Additional file 1: Figure S1 E). IL-6 and VEGF have
both been shown to increase the angiogenic potential of
malignant melanoma. As shown in Figure 1E-F, treat-
ment of Mewo cells with rWNT5A was surprisingly also
found to increase secretion of VEGF in the cell culturesupernatant without affecting the VEGF mRNA levels
(Figure 1E-F). The same pattern, that rWNT5A in-
creases VEGF secretion but not the mRNA expression,
was also seen in the A375 cells (data not shown).
WNT5A siRNA decreases secretion in cell culture
supernatants
To further investigate the effects of WNT5A on produc-
tion of IL-6 and VEGF in melanoma cells, siRNA was
used to knock down the expression of WNT5A in HTB63
cells. The efficiency of the knockdown was determined at
the mRNA level and protein level by Western blot and
QPCR respectively (Figure 2A and B). After WNT5A
knockdown, IL-6 secretion was reduced at 48 h and 72 h
as measured by Elisa (Figure 2C). There was no difference
in IL-6 expression on the mRNA levels neither at 48 h nor
at 72 h (Figure 2D). Secreted VEGF levels were also re-
duced at 48 h and 72 h after siRNA transfection but there
was no difference in mRNA levels after 48 h and 72 h
(Figure 2E-F).
WNT5A increases secretion by inducing exocytosis
In order to investigate the mechanism behind the in-
creased release of IL-6 and VEGF by WNT5A, Mewo
cells were stimulated with rWNT5A for 3 h and subse-
quently paraffin embedded and stained with hematoxylin
and eosin. A prominent cell border was detected in un-
treated cells and this was less pronounced in cells
treated with WNT5A (Figure 3A). We then stained un-
treated cell or cells treated with WNT5A with phal-
loidin, to detect changes in the F-actin cytoskeleton, and
detected a re-organization of F-actin following WNT5A
treatment (Additional file 1: Figure S2 A). In untreated
cells, the F-actin was primarily localized at the cell
cortex whereas in WNT5A stimulated cells (3 h) the
F-actin was primarily localized in the cytosol and less so
in the cortical region. We next analyzed the effects of
rWNT5A on the intracellular levels of IL-6 by Western
blot and found that cell lysate from cells treated with
WNT5A had less IL-6 than cell lysate from cells treated
with carrier (Figure 3B). Furthermore, the rWNT5A-
induced increase of IL-6 levels in Mewo supernatants,
were not significantly affected by Actinomycin D
(Figure 3C), a general inhibitor of transcription. The
increases in IL-6 following WNT5A treatment could
however, be inhibited by pre-treatment with the Ca2+
chelator Bapta and the PKA inhibitor H89 (Figure 3D).
The WNT5A induced exocytosis is dependent on the
small RhoGTPase Cdc42
It has previously been shown that the actin regulatory
protein Cdc42, a small RhoGTPase, is activated by
WNT5A in breast cells and also that it is important for
exocytosis processes in different contexts [29-31]. It was
Figure 1 WNT5A increases secretion of IL-6, IL-8 and VEGF in cell culture supernatants. (A) Western blot of endogenous WNT5A protein
expression in melanoma cell lines Mewo, SkMel28, A2058, A375 and HTB63. Anti-β-actin was used as loading control. Picture is representative of
at least 3 experiments. (B) Mewo cells treated with carrier (0.1% BSA in PBS; Ctrl) or 0.2 μg/ml rWNT5A for 3 h. A set of inflammation cytokines
were measured using BD Cytometric Bead Array (CBA) and both IL-6 and IL-8 were produced upon a short (3 h) rWNT5A stimulation. (C) IL-6
levels in Mewo cell culture supernatants were measured using IL-6 Elisa. Mewo cells were treated with 0.2 μg/ml rWNT5A or carrier for 3, 6, 12, 24
and 48 h and IL-6 in supernatants was measured. The bar graphs show average fold increase as compared to carrier (ctrl) for each time point
indicated. The experiment was performed at least 4 times. Error bars represent SEM. (D) Cells from experiment 1C were used for IL-6 RT-QPCR.
The experiment was performed at least 3 times. Error bars represent SD. (E) Supernatants from 1C were used to measure VEGF levels after WNT5A
treatments. Error bars represent SEM. (F) Cells from 1C were used for VEGF RT-QPCR. The experiment was performed 3 times. Error bars represent
SD. * = p <0.05 by ANOVA test.
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driven angiogenic effects in melanoma [32]. To investi-
gate the involvement of Cdc42 in the present WNT5A
induced effects, we first confirmed that rWNT5A in-
deed activated Cdc42 also in malignant melanoma
Mewo cells (Figure 3E). Since we, and others have
shown that WNT5A activates Cdc42 [5,23], we nextanalyzed whether expression of a dominant negative
(DN) version of either Cdc42 or Rac1 affected the
WNT5A induced exocytosis. We therefore transfected
Mewo cells with DN-Cdc42 or DN-Rac1 prior to a 3 h
rWNT5A stimuli and analyzed the secreted IL-6 and
VEGF levels. As shown in Figure 3F, WNT5A induced
IL-6 secretion was inhibited by both DN-Cdc42 and
Figure 2 WNT5A siRNA decreases IL-6 and VEGF secretion in cell culture supernatants. The efficiency of WNT5A siRNA transfection was
determined using Western blot (A) and RT-QPCR (B) 48 h and 72 h after transfection. Anti-β-actin was used as loading control. Cell culture
supernatants were analyzed for differences in IL-6 protein (C) and VEGF protein using Elisa (E). The experiment was performed at least 3 times.
Error bars represent SEM. Differences in IL-6 (D) and VEGF (F) mRNA from the same experiments were analyzed using RT-QPCR. The experiment
was performed at least 3 times. The bar graphs show average fold decrease as compared to scramble siRNA (ctrl) for each time point indicated.
Error bars represent SD. *** = p <0.001, ** = p <0.01 by ANOVA test.
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Cdc42 and slightly inhibited by DN-Rac1 (Additional
file 1: Figure S2 B).
The WNT5A induced cytokine release is not affected by
TeNT
Cdc42 has previously been shown to activate distinct
exocytosis processes and also to directly bind certain
SNAREs [29-31]. As mentioned above, the VAMPs canbe divided into TeNT-sensitive and -insensitive VAMPs.
To investigate what molecular mechanism that was
affected by WNT5A in more detail we therefore next
performed a secretion experiment, using TeNT. Interes-
tingly, TeNT did not inhibit the WNT5A induced exo-
cytosis of IL-6 (Figure 3G) or VEGF (data not shown).
Neither did Brefeldin A, a general inhibitor of the
classical ER-Golgi secretory pathway (Additional file 1:
Figure S2C).
Figure 3 WNT5A induces a Ca2+- and Cdc42-dependent release of soluble mediators. (A) Mewo cells treated with rWNT5A for 3 h were
paraffin embedded and stained with hematoxylin & eosin (HE). Scalebars = 10 μm. Arrows indicate differences in the cell cortex. (B) IL-6 Western
blot (WB) detecting changes in intracellular IL-6 following cytokine release upon WNT5A treatment for 3 h. (C) Mewo cells treated with DMSO or
Actinomycin D for 12 h together with rWnt5 or carrier. The bar graphs show average fold increase as compared to carrier (ctrl) for each time
point and treatment indicated. Error bars represent SEM. n = 4. (D) Mewo cells were pre-treated with DMSO, the Ca2+-chelator Bapta-AM or PKA
inhibitor H89 for 30 min prior to WNT5A treatment for 3 h. The bar graphs show average fold increase as compared to carrier (ctrl) for each time
point and treatment indicated. Error bars represent SEM. n = 4. (E) Cdc42 is activated by WNT5A in Mewo cells. Western Blot of a GST-Pull down
assay of active Cdc42, upon rWNT5A stimulation for 45 min. Controls are carrier (Ctrl) or rWNT3A for 45 min. (F) Transfection of Mewo cells with
DN-Cdc42 or -Rac1 inhibits the WNT5A induced secretion of IL-6. Empty vector used as control. The data shown are ratios of rWNT5A treated
(3 h)/untreated cells for each plasmid transfected and normalized against the empty vector control. n = 3. (G) Mewo cells were pre-treated with
Tetanus toxin, TeNT, for 30 min prior to WNT5A treatment for 3 h or 24 h. The bar graphs show average fold increase as compared to carrier (ctrl)
for each time point and treatment indicated. Error bars represent SD. n = 2. * = p <0.05 ** = p <0.01 by Student’s t-test. IL-6 levels in supernatants
were detected using Elisa.
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We next chose to investigate the release of MMP2 since
it is a protein that is involved in metastasis and also
is secreted through the classical secretory pathway [33].
Secretion of MMPs is central to control degradation of
extracellular matrix and invasion [34,35]. It has also
been shown that small RhoGTPases promotes MMP2
secretion [36]. Also release of MMP2 was induced by a
short stimulation of rWNT5A (3 h) an effect that lasted
up to 24 h of rWNT5A stimulation (Figure 4A). Just
as for IL-6 and VEGF, the mRNA levels of MMP2
remained unaffected (Figure 4B). We also evaluated
whether DN-Cdc42 and -Rac1 would affect MMP2 re-
lease and as shown in Additional file 1: Figure S2D (left),
overexpression of DN-Cdc42 inhibited the rWNT5A-induced release of MMP2 slightly and to a lesser extent
also by DN-Rac1. Furthermore, neither TeNT nor
Brefeldin A inhibited the rWNT5A induced release
of MMP2 (Figure 4C-D and Additional file 1: Figure S2
D right) indicating that the mechanism behind the
rWNT5A induced secretion of soluble mediators, did
not act via the classical secretion pathway.
We next aimed to investigate a more precise mechanism
behind the rWNT5A-induced secretion. In all initial
experiments (Figures 1, 2, 3, 4), the Elisa’s were performed
using previously frozen lysates. Therefore, we subse-
quently performed experiments using freshly prepared
supernatants from rWNT5A stimulated Mewo cells (3 h)
or supernatant that had gone through two cycles of
freeze/thawing at −80°C/4°C. As shown in Figure 5,
we could see that only supernatants from rWNT5A
Figure 4 WNT5A induces MMP2 release in Mewo cells. (A) MMP2 levels in cell culture supernatants were measured using MMP2 Elisa. Mewo
cells were treated with 0.2 μg/ml rWNT5A or carrier for 3, 6, 12, 24 and 48 h and IL-6 in supernatants was measured. The bar graphs show average
fold increase as compared to carrier (ctrl) for each time point indicated. Error bars represent SEM. The experiment was performed at least 4 times.
(B) Cells from experiment 4A were used for MMP2 RT-QPCR. Error bars represent SD. (C) Mewo cells were pre-treated with Tetanus toxin, TeNT,
for 30 min prior to WNT5A treatment for 24 h. MMP2 levels in cell-culture supernatants were detected using Elisa. The bar graphs show average
fold increase as compared to carrier (ctrl) for each time point and treatment indicated. Error bars represent SEM. n = 2. (D) Mewo cells were
pre-treated with Brefeldin A, Bref A, for 30 min prior to WNT5A treatment for 3 h. MMP2 levels in cell-culture supernatants were detected using
Elisa. The bar graphs show average fold increase as compared to carrier (ctrl) for each time point and treatment indicated. Error bars represent
SEM. n = 4. * = p <0.05 ** = p <0.01 *** = p <0.001 by Student’s t-test.
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showed an increased amount of soluble mediators IL-6
(Figure 5A), VEGF (Figure 5B) and MMP2 (Figure 5C).
The actual concentrations measured are shown in
Additional file 1: Figure S3 A.
rWNT5A induces exosomes release containing the soluble
mediators
One exocytosis mechanism that is known to affect the
concomitant release of a wide variety of mediators is
that of exosomes [19,37]. IL-6 mRNA transcript is in-
duced in immune cells upon exosome stimulation. This
was recently ascribed a mechanism involving TLR2 acti-
vation with subsequent IL-6 mRNA induction [38].
Since we did not observe changes in IL-6 mRNA levels
we decided to analyze the TLR2 expression levels on the
different malignant melanoma cell lines used and found
that, compared to monocyte-derived myeloid dendritic
cells (Mo-mDCs), the malignant melanoma cell lines
(A375, Mewo and HTB63) lacked TLR2 expression
(Additional file 1: Figure S3 B). With this, together withthe observations described in Figure 5 in mind, we next
evaluated whether rWNT5A could induce release of
exosomes containing already pre-formed mediators (eg.
IL-6). We therefore set out to isolate the exosome frac-
tions of rWNT5A stimulated Mewo cells and compared
this to Mewo cells stimulated with carrier or rWNT3A
as control (all stimulations 3 h). First of all, we could
show that the isolated exosome fractions did contain
exosomes by using electronmicroscopy (Figure 6A).
Next, we showed that although the protein GAPDH was
not increased upon rWNT5A stimulation (Figure 6B
upper), the exosome related protein CD63 was (Figure 6B
center). Also the exosome related Rab-protein Rab5b,
was increased in the WNT5A stimulated fractions
(Figure 6B lower). We could finally show that IL-6 and
MMP2 were present in the rWNT5A stimulated exo-
some fractions as measured by Elisa of frozen exosome
samples (Figure 6D-E and Additional file 1: Figure S3
C), while exosome-depleted supernatants from rWNT5A
stimulated Mewo cells did not show elevated levels of
IL-6 after freeze/thawing (Additional file 1: Figure S3 D).
Figure 5 Freeze/thawing releases the soluble mediators from
the supernatants. (A) IL-6 levels as measured by Elisa in cell culture
supernatants of Mewo cells that were treated with 0.2 μg/ml
rWNT5A or carrier for 3 h and subsequently was freshly run on Elisa
(4°C) or freeze/thawed for two cycles −80°C/4°C before analyses. The
bar graphs show average fold increase as compared to carrier (ctrl)
for each treatment indicated. Error bars represent SD. n = 2. (B) VEGF
levels as measured by Elisa in cell culture supernatants of Mewo cells
that were treated with 0.2 μg/ml rWNT5A or carrier for 3 h and
subsequently was freshly run on Elisa (4°C) or freeze/thawed for two
cycles −80°C/4°C before analyses. The bar graphs show average fold
increase as compared to carrier (ctrl) for each treatment indicated.
Error bars represent SD. n = 2. (C) MMP2 levels as measured by Elisa
in cell culture supernatants of Mewo cells that were treated with
0.2 μg/ml rWNT5A or carrier for 3 h and subsequently was freshly
run on Elisa (4°C) or freeze/thawed for two cycles −80°C/4°C before
analyses. The bar graphs show average fold increase as compared to
carrier (ctrl) for each treatment indicated. Error bars represent SD.
n = 2. * = p <0.05; *** = p <0.001 by Student’s t-test.
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on the exosome fractions from rWNT5A stimulated
Mewo cells (3 h) as compared to carrier stimulated
Mewo cells. Although these data should be interpreted
with caution due to low amounts of microRNA, elevated
levels of four microRNAs were significantly increased in
the rWNT5A induced exosomes (ENSG00000202498,
hsa-mir-455, ENSG00000252531 and hsa-mir-593), as
shown in Additional file 1 Table S1. Two of these miR-
NAs have previously been related to various forms of
cancer (hsa-mir-455 [39] hsa-mir-593 [40]).
The WNT5A induced exosome release was dependent
on Cdc42 as shown by transfecting Mewo cells with a
DN-Cdc42, were the WNT5A induced IL-6 levels were
decreased in exosomes specifically (Additional file 1:
Figure S3 E) and not only in the supernatant as pre-
viously shown (Figure 3F). This was strengthened by the
fact that a constitutively active form of Cdc42 (CA-
Cdc42) expressed in Mewo cells induced exosome re-
lease on its own as measured by a quantitative Exosome
ELISA (ExoELISA) (Figure 6C). The WNT5A induced
exosome release was rapid with a maximum level at 3 h
post WNT5A stimulation but also sustained over a long
time period, measured up to 48 h post stimulation (data
not shown). Interestingly, also the WNT3A stimulated
control cells showed a marked increase in exosomal pro-
teins (Figure 6B) but not the soluble mediators IL-6 and
MMP2 (Figure 6D-E).
WNT5A siRNA decreases endothelial cell co-culture
branches
We next wanted to analyze whether the decreased levels
of secreted mediators following WNT5A knockdown
could have a functional implication on angiogenesis.
Therefore, branching assays were performed using the
mouse endothelial cell line MS1 in co-cultures with
Figure 6 WNT5A induces release of exosomes that contain solube mediators. (A) Electronmicroscopic picture of isolated exosome fraction
from supernatant of Mewo cells treated with 0.2 μg/ml rWNT5A for 3 h. (B) Western blot of isolated exosomes from supernatant of Mewo cell
stimulated with 0.2 μg/ml rWNT5A, carrier or 0.1 ng/ml rWNT3A for 3 h. GAPDH (upper), CD63 (center) and Rab5b (lower). (C) Quantitative
Exosome Elisa (ExoELISA) of isolated exosome fraction from Mewo cells transfected with pcDNA3 or CA-Cdc42. The bar graphs show the relative
increase of exosomes produced in CA-Cdc42 transfected as compared to pcDNA3 transfected Mewo cells. Error bars represent SEM. n = 5.
* = p <0.05 by Student’s t-test. (D) IL-6 or (E) MMP2 levels as measured by Elisa of frozen exosome fractions isolated from supernatant of Mewo
cells that were treated with 0.2 μg/ml rWNT5A, carrier or 0.1 ng/ml rWNT3A for 3 h. The low protein yield in the isolated exosome fractions might
explain the higher relative background level in the control as compared to IL-6 measured in supernatant. The bar graphs show average fold
increase as compared to carrier (ctrl) for each treatment indicated. Error bars represent SD. n = 3. * = p <0.05, ** = p <0.01 by Student’s t-test.
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and subsequently seeded on a Matrigel layer. MS1 endo-
thelial cells form tubular networks when cultured in
Matrigel together with tumor cells. There was a decrease
in the total length and in the number of tubes formed
when MS1 cells were cultured together with cells trans-
fected with WNT5A siRNA compared to cells transfected
with Scrambled siRNA (Figure 7A). We also performed
control cultures with MS1 cells only treated with
rWNT5A in order to ensure that WNT5A in itself did
not affect tube formation in the co-cultures (Additional
file 1: Figure S3 F). We then used HTB63 cells that were
pre-treated with Bapta-AM for 30 min before they were
used in co-culture experiments (Figure 7B). There was a
decrease in the total length and number of tubes formed
after Ca2+ chelation compared to cells incubated only with
vehicle (DMSO).To verify that rWNT5A induced Mewo exosomes could
signal to MS1 cells and that this affected angiogenesis re-
lated biological events we next examined the tube network
formation of MS1 cells stimulated with isolated exosomes
from untreated or rWNT5A treatedMewo cells (Figure 7C)
or performed Q-PCR of MS1 cells stimulated with isolated
exosomes from untreated or rWNT5A treated Mewo cells
(3 h chosen as optimal time point) and analyzed induced
expression of angiogenesis related genes (Figure 7D). We
found that exosomes from rWNT5A treated Mewo cells
induced MS1 tube formation (Figure 7C) while exosome-
depleted supernatant from corresponding samples did not
(Figure 7C). Similarly, exosomes from rWNT5A treated
Mewo cells induced an increased expression of both ALK1
and endoglin in MS1 cells using mouse-specific primers,
an effect that was abolished when using exosome-depleted
supernatants as a control (Figure 7D).
Figure 7 WNT5A affects angiogenic processes in malignant melanoma cells. (A) Quantification of total length of tubes (left), quantification
of number of tubes (right), n = 4. Error bars represent SEM. * = p <0.05, ** = p <0.01 (B) MS1 cells grown together with HTB63 treated with DMSO
or Bapta-AM, (left), total length of tubes, (right), number of tubes, n = 3. Error bars represent SEM. * = p <0.05 ** = p <0.01 by paired Student’s
t-test. (C) MS1 cells that had been stimulated with exosomes isolated from carrier- or rWNT5A-treated Mewo cells, or with exosome-depleted
supernatant from the corresponding samples, to analyze the relative total tube length induction, number of tubes, n = 6. Error bars represent
SEM. ** = p <0.01 by paired Student’s t-test. (D) Q-PCR of mRNA from MS1 cells that had been stimulated with exosomes isolated from carrier- or
rWNT5A-treated Mewo cells to analyze angiogenesis related genes using mouse specific primers. Both ALK1 (black bars) and Endoglin (white bars)
expression was enhanced by rWNT5A induced exosomes (exosome fraction; left) whereas the exosome depleted supernatant fraction showed a
loss of function as compared to total supernatant (exosome depleted fraction; right) (E) Correlation between WNT5A and the angiogenesis
marker endothelial cell-selective adhesion molecule (ESAM) mRNA expression levels in a set of 223 primary malignant melanomas [24]. R = 0.31;
Spearman’s rank test P = 7.7 × 10−7.
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http://www.molecular-cancer.com/content/13/1/88To analyze whether WNT5A expression in malignant
melanomas correlated to any known angiogenesis
marker we performed a gene expression data setcorrelation using gene expression data from 223 primary
malignant melanomas in Harbst et al. [24] (Figure 7E).
WNT5A mRNA levels were found to correlate positively
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adhesion molecule (ESAM) mRNA expression levels
(R = 0.31; P = 7.7x10−7). Since the mRNA is originally
prepared from paraffin samples the correlation can be
viewed as a relatively strong.
Discussion
Previous studies have correlated high WNT5A ex-
pression to poor prognosis in melanoma patients [11].
Angiogenesis and expression of immunomodulatory cy-
tokines also correlate to poor prognosis in melanoma
patients [8]. Here we show that, in melanoma cells with
low endogenous WNT5A expression, the stimulation
with rWNT5A induces a rapid release of exosomes con-
taining the immunomodulatory cytokine IL-6 and the
pro-angiogenic factors IL-8, VEGF and MMP2. We also
show that, when cells with a high endogenous WNT5A
expression were depleted of WNT5A, the release was
reduced, suggesting that WNT5A is functioning in an
auto- or paracrine manner. These changes were not ac-
companied by a change in mRNA expression excluding
a possible transcriptional induction of these genes upon
WNT5A signaling. We instead show that the WNT5A-
induced effects on the release of these pro-angiogenic
and immunomodulatory factors, are due to a WNT5A/
Ca2+-regulated release of exosomes containing these me-
diators. In good agreement with this, the inhibitor of
cAMP dependent Kinase (PKA), previously implicated in
cytokine exocytosis [41,42], also inhibited the WNT5A-
induced release of exosomes.
Changes in calcium signaling have been shown to
induce a change in F-actin organization that can allow
for secretory granules to reach the cell membrane and
activate secretion [43]. We and others have previously
shown that WNT5A induces an intracellular calcium
signal in melanoma cells [22,44] and breast cells [5].
Also in this study, the Ca2+-chelator Bapta, inhibited the
effects of WNT5A. Reorganization of F-actin from the
prominent cell cortex towards the cytoplasmic region has
previously been reported to be part of the Ca2+-dependent
exocytosis mechanisms [14]. This has lately been corre-
lated to activation of the small RhoGTPases Cdc42 and
Rac1 [14,16,45] although the RhoGTPases probably me-
diate the vesicular trafficking primarily [14]. WNT5A was
also shown to activate both Cdc42 and to a lesser extent
Rac1 in breast cells [5]. Indeed, we could show that
WNT5A induced activation of Cdc42 also in malignant
melanoma Mewo cells and introduction of DN-Cdc42
and -Rac1 inhibited the WNT5A induced release.
Exosomes are produced by a wide range of mamma-
lian cells and contribute to intercellular communications
[18,19]. The exosomes may contain various molecules,
also soluble mediators such as cytokines (eg. TGFβ and
PGE2) [19,37], chemokines [46] and angiogenic factors(eg. VEGF and MMP2) [47]. It is known that exosomes
act immunomodulatory on myeloid cells [18,48]. In im-
mune cells, IL-6 and IL-8 mRNA expression has pre-
viously been connected to exosome signaling. Due to the
fact that IL-6 mRNA levels remained unaffected in our
study we believe that the mechanism behind WNT5A
induced IL-6 release in malignant melanoma cells is
Myd88/TLR2 independent [38,49]. Indeed, TLR2 was
not expressed in the cell lines used in this study. We
recently showed that also rWNT5A possess immuno-
modulatory effects on human monocytes. The findings
in this study might explain why we observed a WNT5A
specific induction of IL-6 and IL-10 mRNA in primary
human monocytes that express TLRs at high levels
specifically [27]. We now show, that in malignant me-
lanoma cells, the induction of immunomodulatory and
pro-angiogenic mediators are not caused by trans-
criptional activation, but by exosome-release of already
formed proteins. Tumor cells generally have an increased
exosome secretion that has been linked to angiogenesis,
metastatic spread and immunosuppression [18]. A pre-
vious study even showed that the tumor microenvi-
ronment was able to specifically promote sorting of
immunosuppressive factors into exosomes [37].
Exosome secretion is dependent on cytoskeletal reorga-
nization and although it has previously been shown that
the exosome dependent protein Rab35, can mediate the
transport of Cdc42 to the plasma membrane to remodel
the actin-structures [21], Cdc42 itself has not been con-
nected to exosome release in mammals. In yeast however,
Sec4p a Rab5b related protein, was shown to interact with
Cdc42 to induce exocytosis [50]. Just as in the WNT5A
induced malignant melanoma exosomes, Rab5b was
expressed in plasma-derived exosomes from malignant
melanoma patients [51]. Also, Rab5b was recently shown
to participate in exosome-formation in malignant mela-
noma cells [20]. We propose that the mechanism behind
the WNT5A induced exosome-release is Ca2+- and
small RhoGTPase-regulated, affecting downstream pro-
teins such as Rab5b and related Rab-family proteins
[18-20,51]. It should not be excluded that also other
Ca2+-regulated proteins, affecting cortical F-actin disas-
sembly, could affect the exosome release [52,53]. In this
study, even the canonical WNT3A protein induced an
increase in exosome-release. We suggest that an in-
dependent signaling pathway, distinct from the Ca2+-
induced, non-canonical WNT5A-pathway, causes this
release. Strengthening this hypothesis, the exosomes pro-
duced by canonical WNT3A displayed a different content
as compared to those produced by non-canonical WNT5A
signaling. Or it could be explained by the recent finding
that indeed Wnt proteins (WNT3A and WNT5A) are se-
creted on exosomes [54,55]. It has long been known in the
Wnt field that WNT5A can induce expression of it self.
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data in this study together with the mentioned studies
might partly explain how this loop could work.
Although numerous articles describing the effects of
WNT5A on intracellular signaling proteins have been
published, few studies concerning WNT5A and tran-
scriptional regulation are available. We also show that
WNT5A does not affect the factors analyzed in this
study at the transcriptional level.Conclusion
In the present study we present novel data showing that
the non-canonical Wnt protein WNT5A, has an effect on
release of exosomes containing immunomodulatory and
pro-angiogenic factors in malignant melanoma cells. This
might have an impact on angiogenic processes in malig-
nant melanomas as supported by our finding that indeed
the expression of WNT5A correlates to that of the angio-
genesis associated gene ESAM in a gene expression data
set correlation of 223 malignant melanomas, and also has
a biological effect on in vitro branching experiments using
endothelial co-cultures. We suggest that, by affecting the
exocytosis of numerous secreted factors in sensitive sys-
tems such as the cell rich microenvironment of a tumor,
WNT5A signaling can have a much wider biological con-
sequence than has previously been described.Methods
Cell culture and treatments
All malignant melanoma cell lines were purchased from
the American Type Tissue Collection (ATCC, Manassas,
VA). MS1 murine endothelial cells [56] were a gift from
Professor Kristian Pietras, (Lund University, Sweden). Re-
combinant proteins (rWNT5A (0.2 μg/ml) or rWNT3A
(0.05 μg/ml) were from R&D systems, Minneapolis, MN.
All chemicals and inhibitors were purchased from Sigma
Aldrich (St Louis, MO.) unless otherwise noted and used
at concentrations: 10 μM Bapta-AM or DMSO control,
5 μM PKA inhibitor H89, 10 ng/ml Tetanus Toxin or
10 μg/ml Brefeldin A. The antibodies used were Goat
anti-WNT5A (R&D systems, Minneapolis, MN), anti-
CD63, anti-Rab5B and anti-GAPDH (Santa Cruz biotech-
nologies), mouse anti-β-actin (MP biomedicals). For BD
Cytometric Bead Array (CBA) the Human Inflammation
Kit was used (BD Biosciences). For hematoxylin and eosin
cells were fixed in 4% PFA and embedded in paraffin and
then stained. F-actin cytoskeleton was stained using
Alexafluor546-coupled Phalliodin. For ELISAs Quantikine
Human IL-6 ELISA kit, Quantikine Human MMP2 ELISA
kit and Quantikine Human VEGF ELISA kit from R&D
systems (Minneapolis, MN) was used. Exosome Elisa
(ExoELISA) CD63 ExoELISATM from System Biosciences
(Uden, The Netherlands) was used.RNA extraction and RT-QPCR
mRNA expression was analyzed using RT-QPCR. RNA was
extracted using RNeasy kit (Qiagen, Hilden, Germany). For
primer sequences, see Additional file 1: Figure S4 and [57].
Transfection and knockdown experiments using siRNA
For overexpression of CA-Cdc42, DN-Cdc42 and Rac1
(N17), Mewo cells were transfected using 1 μg plasmid
(a kind gift from Dr Pontus Aspenström, (Karolinska
Institutet, Sweden) per 24-well. 2 μg CA-Cdc42, DN-
Cdc42 or pcDNA3.1 was used per 6-well for ExoELISA
experiments. For knockdown experiments 150000 HTB63
cells were transfected with Silencer Select siRNA against
WNT5A (10nM, Applied Biosystems Carlsbad CA) and
the appropriate concentrations of scrambled siRNA as
control.
MS1 Co-culture experiments
Co-culture experiments were performed as previously
published [58]. For exosome stimulation experiments,
MS1 cells were seeded in gelatine-coated 12-well plates
and stimulated with exosome-enriched or –depleted frac-
tions from carrier or rWNT5A (0.3 μg/ml, 3 h) stimulated
Mewo cells (see below). The primers used for angiogenesis
specific Q-PCR of the MS1 cells have been published pre-
viously [57].
Exosome isolation
Mewo cells were cultured over night in serum free Eagle’s
Minimum Essential Medium supplemented with peni-
cillin/streptomycin that had been Ultracentrifuged for 2 h
at 100,000 g using Beckman Optima TLX Ultracentrifuge.
The medium was replaced by fresh Ultracentrifuged
medium and cells were stimulated with carrier, rWNT3A
or rWNT5A as indicated for 3 h. The supernatants were
collected and exosome isolation was carried out by dif-
ferential centrifugation. Briefly, the supernatants were
centrifuged for 300 g for 10 min to remove debris. The
supernatants were then centrifuged once at 2,000 g for
15 min, once at 10,000 g for 30 min and finally exosomes
were pelleted at 100,000 g for 1,5-2 h.
Exosome identification by electron microscopy
The exosome enriched pellet was diluted in 50 μl PBS and
kept at 4°C until EM analysis. A drop of the exosome sam-
ple was placed on a carbon coated copper grid and was let
to adhere for 1 min. The sample was contrast stained by
adding a drop of 2% uranyl acetate to the sample on the
grid. Excess liquid was removed by gently using an ab-
sorbing paper, before positioning the grid on a paper with
the coated side up and was let to air dry for 5 minutes.
The preparation was examined using an electron micro-
scope FEI Tecnai spirit at 100 KV.
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MicroRNA expression analyses were performed using Affy-
metrix miRNA-3_0 arrays according to the manufacturer’s
instructions (Affymetrix, Santa Clara, CA). These array ex-
periments were performed at Swegene Centre for Integra-
tive Biology (SCIBLU) at Lund University. Microarray data
were initially pre-processed and normalized using Robust
Multi-array Analysis (RMA) method [59]. These analyses
were performed using Affymetrix Expression Console Soft-
ware v1.1.2. To identify significantly differentially expressed
miRNAs between carrier stimulated and rWNT5A stimu-
lated Mewo-exosomes, we used significance analysis of
microarrays (SAM) method [60]. SAM analyses were per-
formed using TMEV v4.0 software.
Statistical analysis
All data was analyzed using Graphpad Prism software and
is visualized as mean with error bars representing stan-
dard deviation (SD) or standard error of the mean (SEM).
Statistical significance was calculated using ANOVA
or Student’s t-test as indicated in the Figure legends.
Spearman’s rank test was used for the statistical analysis of
the gene expression data set. The malignant melanoma
mRNA data set has previously been published [24] and
approved by the local ethics committee of Lund University
(Dnr 191/2007). The mRNA was prepared from paraffin
embedded samples of 223 primary malignant melanomas.
Additional file
Additional file 1: Table S1. miRNA microarray of RNA isolated from
Mewo exosomes stimulated or not with rWNT5A for 3h. Figure S1. IL-6 and
VEGF is increased in A375 cell culture supernatants after Wnt5a treatment (A).
(B) Corresponding RT-QPCR for IL-6. (C-D) As in (A-B) but measuring IL-6
using A2058 cells. (E) Mewo cells treated with PMA/ionomycin (12h) as
positive control for RT-QPCR (IL-6). Figure S2. (A) Mewo cells treated with
rWNT5A for 3h stained with phalloidin to visualize F-actin. (B and D)
Transfection of Mewo cells with DN-Cdc42, but not -Rac1, inhibits the
Wnt5a induced secretion of VEGF (B) or MMP (D). The control cells were
transfected with an empty vector. (C and D) Mewo cells were pre-treated
with Brefeldin A for 30min prior to Wnt5a treatment for 3h. Figure S3. (A)
IL-6, VEGF and MMP2 levels (actual concentration) as measured by Elisa of
non-frozen or freeze-thawed cell culture supernatants of Mewo cells that
were treated with rWNT5A or carrier (3h) n = 2. (B) Western blot of TLR2 in
Mo-mDCs (Ctrl), A375, Mewo and HTB63 cells. (C) IL-6 or MMP2 levels (actual
concentration) as measured by Elisa of frozen exosome fractions isolated
from supernatant of Mewo cells that were treated with 0.2μg/ml rWNT5A,
carrier or 0.1ng/ml rWnt3a for 3h. (D) Induction of IL-6 levels in unfractionated
supernatants of rWNT5A stimulated Mewo cells (ratio; black bars) but not in
exosome-depleted supernatants of rWNT5A stimulated Mewo cells (ratio;
white bars). (E) IL-6 levels in frozen exosome fractions isolated from
supernatant of transfected and treated Mewo cells as indicated. (F) MS1 cells
grown alone and treated with carrier or rWNT5A, total length of tubes (left),
number of tubes (right). Figure S4. Table of primers used for Q-PCR.
* = p <0.05; ** = p <0.01; *** = p <0.001 by Student’s t-test. n=3-7 unless
otherwise stated.
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